CST: 24/07/2016 01:52:57   

Eastgate Biotech Receives Repeat Purchase Order From Its Canadian Distributor

199 Days ago

SALT LAKE CITY, UT and TORONTO, ON--(Marketwired - Jan 6, 2016) - EastGate Biotech Corp. (OTC PINK: ETBI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules has received a repeat purchase order from its Canadian distributor Preferred Nutrition (www.pno.ca). As per the agreed upon sales terms the company has received a cash deposit for this order.

Preferred Nutrition placed an order for E-drops which is the company's natural and herbal alternative that assists to rid the body of UTI infections painlessly and effectively without side effects of synthetic drugs. Preferred Nutrition markets this product under its own label UTI drops (http://utidrops.com). To date, the number of health food stores that carry UTI drops is up to 370 across Canada.

Preferred Nutrition Inc. Is a Canadian premier distribution company founded in 2002. It primarily distributes to approximately1200 health food stores across Canada. It represents 5 top product lines for a total of 78 products in the vitamin and supplement category.

Information on EastGate's natural product line can be found at www.nano-essentials.com

"We are pleased to have received this repeat purchase order from Preferred Nutrition" says Anna Gluskin, EastGate's CEO. "This positive feedback on the product from customers is encouraging as we continue to reach out and hopefully add more distributors this coming year" continues Gluskin.

Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbour" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.

The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates", "forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential", "projected", "pursue", "strategy", "study", "targets", or "believes", or variations of or similar such words and phrases or statements that certain actions, events or results "may", "could", "would", or "should", "might", or "way forward", "will be taken", "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement.EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:
Rose Perri
1-647-692-0652
Email: Email Contact
Website:www.EastGateBiotech.com